By MATTHEW HOLT The big news in the comeback of digital health is that Hinge Health filed its S1 and is looking to go public soon. I suspect that they’d have preferred to get the IPO done late last year when the AI bubble was expanding rather than deflating, but timing the market is tough!…
When Anna Nusslock showed up at her local hospital 15 weeks pregnant and in severe pain earlier this year, she said, a doctor delivered devastating news: The twins she and her husband had so desperately wanted were not viable. Further, her own health was in danger, and she needed an emergency abortion to prevent hemorrhaging…
Antares Therapeutics spun off of Scorpion Therapeutics, a clinical-stage biotech that Eli Lilly acquired earlier this year. Like Scorpion, Antares is developing small molecules that go after undruggable targets in cancer. The post Cancer Drug Startup Antares Unveils $177M to Pick Up Where Scorpion Therapeutics Left Off appeared first on MedCity News.
Contingency management is an evidence-based psychosocial intervention that uses motivational incentives, such as vouchers or gift cards, to encourage recovery behaviors like stimulant abstinence and treatment session (e.g., cognitive behavioral therapy, group therapy) attendance. The Biden administration has approved four state contingency management waivers (California, Delaware, Montana, and Washington); three additional state contingency management requests…
The fatty liver disease MASH is one of the metabolic disorders that Nula Therapeutics is pursuing. The startup’s small molecules are intended to restore the integrity of the nuclear envelope, a cellular membrane whose dysfunction can contribute to metabolic disease. The post Startup Nula Emerges to Advance a New Class Medicines for Metabolic Disease appeared…
Takeda said more than half of plaque psoriasis patients treated with zasocitinib achieved clear or almost clear skin in two Phase 3 studies. Regulatory submissions for the TYK2 inhibitor are planned for 2026 and clinical trials are ongoing in other indications. The post Takeda Drug From $4B Deal Succeeds in Two Pivotal Plaque Psoriasis Trials…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions. The post FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions appeared first on MedCity News.
How top-to-bottom collaboration can alleviate hurdles and help increase equitable access to the most effective treatments for all cancer patients. The post Closing the Gap: Advancing Precision Oncology Through Education and Collaboration appeared first on MedCity News.
On February 14, 2026, CMS released a dataset with provider-level spending data that the agency suggests could be used to identify unusual billing patterns for specific services, states, or providers. This policy watch describes what the data include, what they exclude, and how they could potentially lead to mistaken conclusions given the limitations of the…